The Star-Ledger - NJ.com
Bristol-Myers fourth quarter below analysts estimates
The Pharma Letter
This concludes a year in which the company received important new product approvals for Yervoy (ipilimumab) for the treatment of metastatic melanoma and kidney transplant rejection drug Nulojix (belatacept) in both the USA and Europe, ...
Bristol-Myers Squibb Reports Mixed Estimates For Q4 (BMY)